MTOR and primary effusion lymphoma: An ATP-competitive inhibitor of mTOR, MLN0128 (sapanisertib), induces apoptosis in PEL cells and reduces the growth of PEL in a xenograft model at nanomolar IC50 concentrations and is still effective against doxorubicin- or rapamycin-resistant PEL cell clones [129].